Ascentage Pharma Group International American Depository Shares

Ascentage Pharma announced seventeen clinical updates from its core assets at the 31st European Hematology Association Congress, including eight poster presentations. Key data showed olverembatinib demonstrated deep and durable responses in chronic myeloid leukemia (CML) patients resistant to first-line therapy and robust clinical response in Phi...

Ascentage Pharma presented clinical data on alrizomadlin (APG-115), an MDM2-p53 inhibitor, for treating pediatric solid tumors at ASCO 2026. The drug showed preliminary antitumor activity with manageable safety profiles as monotherapy and in combination with lisaftoclax, achieving a 23.5% objective response rate in the combination arm. Alrizomadl...

Ascentage Pharma announced Phase Ib study results showing olverembatinib combined with blinatumomab demonstrated encouraging clinical activity in patients with relapsed/refractory Ph+ BCP-ALL or CML-LBP, with 91% achieving complete response and manageable safety profile. The company presented six studies across three key assets at the 2026 ASCO A...

Ascentage Pharma presented updated clinical data at ASCO 2026 showing olverembatinib achieved a 91.3% complete cytogenetic response rate and 60.9% major molecular response rate at cycle 24 in CML-CP patients as second-line therapy. The drug demonstrated a stable safety profile with no new safety signals, supporting its potential role in treating ...

Ascentage Pharma Group International announced that 17 clinical advances of its core assets, including 8 poster presentations, will be featured at the 31st Congress of the European Hematology Association (EHA2026) in Stockholm from June 11-14, 2026. The presentations showcase data from ongoing clinical studies of Olverembatinib (HQP1351), China's...